Should you wait until GLP-1 prices come down? It is a fair question and the market has been moving in your direction, so the answer deserves real numbers instead of a pep talk. As published in September 2026, Zepbound vials ran $299 to $449 a month depending on dose through LillyDirect, Wegovy vials ran $349 to $549 and the new oral option Foundayo (orforglipron) arrived from $149 a month at the lowest dose after its FDA approval on April 1, 2026. For Medicare beneficiaries the Medicare GLP-1 Bridge now prices eligible Part D enrollees at $50 a month through December 31, 2027. Those are real declines. Whether they justify waiting depends on one thing the price lists never mention, which is what your body does during the years you spend waiting.

Key takeaways
  • Self-pay prices have fallen and the dated figures are real, with Wegovy vials at $349 to $549 and Zepbound vials at $299 to $449 in September 2026.
  • The oral option Foundayo launched from $149 a month at the lowest dose after its April 1, 2026 approval.
  • The Medicare GLP-1 Bridge prices eligible Part D enrollees at $50 a month through December 31, 2027.
  • Insulin resistance compounds while you wait and the markers that predict heart disease move in one direction the whole time.
  • A flat fee makes the price conversation simpler, because the fee never rises when the dose does.

What the market has actually done to prices

The movement is real and worth respecting. Cash-pay vial programs that started in the five hundreds now sit well below that. Wegovy vials through the manufacturer's own channel ran $349 to $549 a month depending on dose as published in September 2026 and Zepbound vials ran $299 to $449 across their dose tiers in the same window. The oral option changed the floor entirely, because a pill is cheaper to make and ship than a cold-chain injectable and Foundayo's lowest dose entered the market at $149 a month. If you are on Medicare, the bridge program changed the math most of all, pricing eligible Part D enrollees at $50 a month for the window that runs July 1, 2026 through December 31, 2027.

Every one of those numbers carries a date because the market reprices several times a year. A page that quotes them without a month attached is stale the day you read it. We restate them with dates and we verify against the manufacturer's own pages rather than against another clinic's blog, because the whole point of the exercise is arithmetic you can check.

The compounding cost of the year you spend waiting

Now the other side of the ledger, which no discount program advertises. If the reason you are asking about prices is that you are insulin resistant, prediabetic or carrying elevated ApoB, then the year you spend waiting is not a neutral holding period. Insulin resistance does not pause. A1c trends do not pause. The inflammation markers and the lipoprotein burden that predict cardiovascular events do not pause. Over a decade of unmanaged insulin resistance, the odds of crossing from prediabetes into type 2 diabetes are high and the trials that established these medications were built on exactly that population, because the medicine works best when the metabolic system is caught early rather than late.

Clinical note

The price fell every year. So did the years. The question is what the waiting costs and the answer is measured in markers, not dollars.

The honest version of the wait math therefore has two columns. In one column, the savings from starting at a future price instead of today's. In the other, the twelve months of continued metabolic drift, the lost year of the medication's benefit and the possibility that the indication or the panel has moved by the time you return. For a patient whose fasting insulin has never been drawn and whose A1c crept from 5.6 to 6.0 over two years, the second column is not small. We will not pretend the savings column is zero either. We will simply insist that both columns appear on the same page, which is more than most price pages offer.

When waiting is genuinely the right call

There are readers this article should actively release, because waiting is correct for them and joining today would be wrong. If your metabolic panel is clean and your reason for considering a GLP-1 is cosmetic, waiting costs you nothing clinical and the price will likely be lower next year. If your history or family history rules the medication out, for instance a personal or family history of medullary thyroid carcinoma or MEN2, no price matters at all. If you are pregnant or planning pregnancy, this is not a waiting question, it is a different clinical conversation entirely. And if you have a clinician you trust who will run the panel and manage the dose with you, at any price point, the relationship is the asset and the price is secondary.

The reader the wait argument fails is the one whose labs show the trend already moving and whose plan for the wait is to do nothing measurable in the meantime. For that person the cheapest month has never been the cheapest outcome. The Biomarker Audit reads ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin, a full lipid panel and thyroid measures and it repeats every 90 days, so the drift the waiting hides is exactly the drift the panel would have caught.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

How the fee structure removes the worst part of the math

The price conversation has a second layer under the medication and it is the layer that actually decides whether the program is affordable over years. Medication price is dose-tiered. A patient on the higher Zepbound vial tier pays meaningfully more every month than a patient on the lower tier and a program that charges more as the dose climbs profits from your titration. That is the fee you cannot predict in advance and it is the one that quietly doubles a program's sticker price over a year.

Our structure is built to take that layer off the table. The membership is one flat $299 a month covering the clinical relationship, four quarterly Biomarker Audits, asynchronous messaging with the care team and video visits. It never rises with the dose and there is no molecule upcharge, because medication is a separate charge billed by the pharmacy you choose at that pharmacy's own price. We set nothing, see nothing and take nothing on it. The membership starts with a $598 hold on your card covering the first two months, charged only once a clinician accepts you into care and released if the clinician cannot accept you. Once accepted, the first two months are charged and nonrefundable. From month three the membership is month to month.

What this does to the wait question is simple. The part of the price that fell is the pharmacy part and the pharmacy part is the part that was always going to keep moving. The part that stays flat is the clinical part and the clinical part is the part that decides whether the medication works. If you start care and the dose turns out to be the lowest tier, your total monthly cost lands near the bottom of the market. If your body needs the top tier, your fee does not punish you for it. Either way the titration follows the evidence rather than the billing schedule.

What we tell patients who are genuinely torn

If you are torn, here is the sequence that costs almost nothing and settles the question with data instead of feelings. Get the panel drawn. Anywhere. If your fasting insulin, A1c and ApoB come back in a range you and a clinician both consider acceptable, waiting is defensible and you have a baseline to recheck in six months. If they do not, you have turned an abstract price question into a concrete clinical one and the extra dollars of starting now are against a measured need rather than a vague intention. The eligibility check takes a few minutes and a clinician reviews every application and you are never charged unless a clinician accepts you into care, so the decision point costs nothing to reach.

FAQ

Should you wait until GLP-1 prices come down?

If your metabolic panel is clean and your interest is elective, waiting is defensible because self-pay prices have been falling. If you are insulin resistant or prediabetic, the year of waiting carries a metabolic cost the price lists never show and the honest math puts both columns on the same page.

How much do GLP-1 medications cost in 2026?

As published in September 2026, Zepbound vials ran $299 to $449 a month by dose through LillyDirect and Wegovy vials ran $349 to $549. Foundayo, the oral option, launched from $149 a month at the lowest dose after its April 1, 2026 approval. All figures are dated because the market reprices often.

Is there a cheaper path for Medicare patients?

Yes. The Medicare GLP-1 Bridge prices eligible Part D enrollees at $50 a month for the window running July 1, 2026 through December 31, 2027. Eligibility questions belong to CMS and your plan.

Will prices keep falling?

The trend is real but no one can promise its direction over any particular year. Pricing depends on manufacturing scale, competition and manufacturer decisions, which is why we publish figures with dates instead of forecasts.

Does the membership fee change with the medication price?

No. The fee is one flat $299 a month at any dose. Medication is billed by your pharmacy at its own price as a separate charge and we take nothing on it, so a price move at the pharmacy moves your pharmacy line and nothing on our side.

What should I do while deciding?

Get the panel drawn. Fasting insulin, HbA1c, ApoB and the rest of the audit set turn an abstract wait into a measured decision and they give any future clinician the baseline they would need anyway.

What does it cost to find out whether I qualify?

Nothing. The eligibility check is free, a clinician reviews every application and the $598 hold is charged only once a clinician accepts you into care. If you cannot be accepted, the hold is released and you are never charged.

One last thing

Waiting is a strategy only when you measure what it costs. The price of the medicine is published and it changes. The price of the year is written in fasting insulin and ApoB and it is private until somebody draws it. Draw the panel first and the wait question answers itself.

Related guides

References

  1. Eli Lilly, FDA approval announcement for Foundayo (orforglipron), April 2026. investor.lilly.com
  2. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge program. cms.gov
  3. FDA, concerns about unapproved GLP-1 drugs used for weight loss, current as of October 1, 2026. fda.gov